2025-522500-24-00招募中3 期
IMCISION: Towards organ preservation and cure via ultra-short immunotherapy in advanced oral cancer. The IMCISION II trial, an investigator-initiated multicentre randomised phase 3 trial (M24IMS)
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting7 个研究点 分布在 1 个国家目标入组 308 人开始时间: 2025年12月12日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 308
- 试验地点
- 7
- 主要终点
- The percentage of patients in arm A with a CCR and organ preservation of the face and oral cavity at 24 months of FU*. Success is defined with a lower bound of the 95% CI >10%.
研究概览
简要总结
To determine the rate of patients with a CCR with organ preservation of the face and oral cavity at two years of FU without compromising clinical outcome for all patients.
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •18 years of age or older
- •Patients willing and able to understand the Dutch study information and protocol requirements and comply with the treatment/intervention schedule, scheduled visits, and other requirements of the study.
- •Primary advanced oral cavity squamous cell carcinoma (HNSCC) o Stage III-IVA according to TNM version 8.0 of the UICC/AJCC staging manual.
- •Primary tumour site: o Malignant neoplasm of other and unspecified parts of tongue (C02.0-C02.3, C02.8-9) o Malignant neoplasm of gum (C03) o Malignant neoplasm of floor of mouth (C04) o Malignant neoplasm of hard palate (C05.0, C05.8-9) o Malignant neoplasm of other and unspecified parts of mouth (C06)
- •Indication for SOC*
- •No prior systemic oncological therapy
- •No prior radiotherapy to the head and neck
- •No immunosuppression
- •World Health Organisation (WHO) performance status of 0-2
- •Screening laboratory values must meet the following criteria: o WBC ≥ 2.0x109 /L o Neutrophils ≥1.5x109 /L o Platelets ≥100 x109 /L o Hemoglobin ≥5.5 mmol/L o Creatinine ≤1.5x upper limit of normal (ULN) o AST ≤ 1.5 x ULN o ALT ≤ 1.5 x ULN o Bilirubin ≤1.5 X ULN (except patients with Gilbert Syndrome, who are eligible when total bilirubin < 3.0 mg/dL) o Women of child-bearing potential (WOCBP) must use appropriate method(s) of con-traception. They should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required time for nivolumab to undergo five x T1/2, ipilimumab has a much shorter T1/2) after the last dose of the IMP. o WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25IU/L or equivalent units of HCG) prior to the start of ICB.
排除标准
- •Inoperable OSCC (Stage IVB)
- •Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids (up to 10 mg of prednisone per day is allowed)
- •Patients who are pregnant or breastfeeding
- •History of allergy to study drug components and/or history of severe hypersensitivity to any monoclonal antibody
- •Use of other investigational drugs 30 days before study drug administration and 5 half times before study inclusion
- •Distantly metastasized (Stage IVC) OSCC
- •Prior irradiation in the head and neck area.
- •Prior anti-PD(L)1 or anti-CTLA4 immune checkpoint-blockade.
- •Prior diagnosed malignancies, except malignancies with a 2 year survival rate of over >90% (eg. certain skin cancers, low-grade prostate carcinoma) and where treatment does not interfere with the treatment of patients included in this trial.
- •Active human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
- •Positive test for hepatitis B virus surface antigen (HBsAg) or hepatitis C antibody (HCV Ab)
- •Subjects with any active autoimmune disease or a documented history of autoimmune disease, except: o Subjects with vitiligo o Resolved childhood asthma/atopy o Residual hypothyroidism due to an autoimmune condition requiring only hormone replacement o Psoriasis without the need for systemic treatment o Any condition not expected to recur in the absence of an external trigger.
- •Underlying medical conditions that, in the investigator's opinion, will make the administration of the study drug hazardous or obscure the interpretation of toxicity or AEs
结局指标
主要结局
The percentage of patients in arm A with a CCR and organ preservation of the face and oral cavity at 24 months of FU*. Success is defined with a lower bound of the 95% CI >10%.
The percentage of patients in arm A with a CCR and organ preservation of the face and oral cavity at 24 months of FU*. Success is defined with a lower bound of the 95% CI >10%.
Non-inferiority of arm A compared to arm B in Recurrence Free Survival (RFS) after a minimum FU of 24 months since randomisation for each patient. An event is defined as disease progression to unresectable disease before surgery or before adjuvant (C)RT, OR recurrent disease after treatment, OR death due to any cause.
Non-inferiority of arm A compared to arm B in Recurrence Free Survival (RFS) after a minimum FU of 24 months since randomisation for each patient. An event is defined as disease progression to unresectable disease before surgery or before adjuvant (C)RT, OR recurrent disease after treatment, OR death due to any cause.
次要结局
- Treatment duration and stops of ARM A will be compared to ARM B.
- The CCR rate in ARM A at 12 and 18 months
- To assess the difference in Qol between Arm A and B on all domains of the EORTC QLQ H&N43 and the EORTC QLQ-C30, EQ-5D-5L, HADS. • And between the responders in Arm A vs Arm B. • And between the non-responders of Arm A vs Arm B. • And between responders and non-responders of arm A
- Compare other survival endpoints between Arm A and B (Locoregional control (LRC), dis-tant metastasis free survival (DMFS), Disease specific survival (DSS), Recurrence Free Sur-vival (RFS), Event Free Survival (EFS) and Overall survival (OS)) at 12, 18 and 24 months FU
- Compare AEs and ir-AEs in both arms using the CTCAE v5.0 and Clavien-Dindo up to 100 days after last treatment (immunotherapy, surgery or adjuvant (C)RT)
- Cost-effectiveness of ARM A will be compared to ARM B in terms of incremental costs and quality adjusted life years
- Extent of surgery (type and hours), RT( days and total Gy), chemotherapy (typaeand cumulative dose), days of admission on the ward, visits, other interventions, etc. • Comparison between ARM A and B • Between the responders in Arm A vs Arm B. • And between the non-responders of Arm A vs Arm B. • And between responders and non-responders of arm A
研究者
Prof. dr. Lotje (C.L.) Zuur
Scientific
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
研究点 (7)
Loading locations...
相似试验
尚未招募
2/3 期
Eliminate TrialThis trial will consider omission of radiotherapy to the neck in patients with N0/N1 nodal status for oral cavity carcinomas with high risk featuresCTRI/2022/02/040311NCI AIIMSJhajjar396
尚未招募
不适用
Clinical And Radiological Evaluations Of Irregularly Placed Mandibular Wisdom Tooth After Removing The Upper Tooth Structure And Leaving The Root In The SocketCTRI/2021/04/032997Dr Joon Sunil16
招募中
2 期
Human Craniomaxillofacial AllotransplantationFacial InjuriesTraumatic Wounds and InjuriesCraniofacial InjuriesCraniofacial DefectsFacial TransplantationFacial DeformityNCT01889381Johns Hopkins University15
已完成
不适用
Intraoperative control of maxillary malignancy resection with cone-beam computed tomographymaxillary cancerupper jaw malignant tumor10019190NL-OMON43222Antoni van Leeuwenhoek Ziekenhuis6
Unknown
2 期
Neoadjuvant Chemoradiotherapy Combined With Perioperative Toripalimab in Locally Advanced Esophageal CancerAdvanced Esophageal Squamous Cell CancerNCT04437212RenJi Hospital20